The trial met its primary safety and efficacy endpoints, demonstrating the device's superiority to oral anticoagulants.

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Boston Scientific, Medtronic and J&J are moving quickly to secure their place in the fast-growing pulsed field ablation space ...

Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...

CEO Geoff Martha said the business did not meet internal growth expectations last quarter due to third-party supply issues ...

Left atrial appendage closure is an alternative strategy for stroke prophylaxis, Wazni and colleagues noted. "The safety and ...

Marlborough, Massachusetts Tuesday, November 19, 2024, 17:00 Hrs [IST] ...

Marie Thibault, an analyst from BTIG, maintained the Buy rating on Boston Scientific (BSX – Research Report). The associated price target ...